tbuckley/cabot-search huggingface dataset:
Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK
Authors: Pingmei Huang, Fenfen Ji, Alvin Ho-Kwan Cheung, Kaili Fu, Qiming Zhou, Xiao Ding, Danyu Chen, Yufeng Lin, Luyao Wang, Ying Jiao, Eagle S.H. Chu, Wei Kang, Ka Fai To, Jun Yu, Chi Chun Wong
Journal: Cell Host & Microbe (2024)

Peptostreptococcus stomatis (P. stomatis) is enriched in colorectal cancer (CRC), but its causality and translational implications in CRC are unknown. Here, we show that P. stomatis accelerates colonic tumorigenesis in Apc
Neuropathological Lesions and Cognitive Abilities in Black and White Older Adults in Brazil
Authors: Claudia K. Suemoto, Renata E. P. Leite, Vitor R. Paes, Roberta Rodriguez, Alberto F. O. Justo, Michel S. Naslavsky, Mayana Zatz, Carlos A. Pasqualucci, Ricardo Nitrini, Eduardo Ferriolli, Wilson Jacob-Filho, Lea T. Grinberg
Journal: JAMA Network Open (2024)

Race differences in dementia prevalence and incidence have previously been reported, with higher dementia burden in Black decedents. However, previous neuropathological studies were conducted mostly in convenience samples with White participants; conducting clinicopathological studies across populations is crucial for understanding the underlying dementia causes in individuals from different racial backgrounds.
Website Content and Funding of Officially Recognized Disease Awareness Campaigns
Authors: Minna Johansson, Loai Albarqouni, Mary O’Keeffe, Karsten Juhl Jørgensen, Steven Woloshin
Journal: JAMA (2024)

This study examines the content, including mention of benefits and harms of testing and treatment, and funding of disease awareness campaign websites recognized by major noncommercial institutions.
Spatial transcriptome mapping of the desmoplastic growth pattern of colorectal liver metastases by in situ sequencing reveals a biologically relevant zonation of the desmoplastic rim
Authors: Axel Andersson, Maria Escriva Conde, Olga Surova, Peter Vermeulen, Carolina Wählby, Mats Nilsson, Hanna Nyström
Journal: Clinical Cancer Research (2024)

We describe the fibrotic rim formed in the desmoplastic histopathologic growth pattern (DHGP) of colorectal cancer liver metastasis (CLM) using in situ sequencing (ISS). The origin of the desmoplastic rim is still a matter of debate, and the detailed cellular organization has not yet been fully elucidated. Understanding the biology of the DHGP in CLM can lead to targeted treatment and improve survival.
B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma
Authors: Wanting Qiang, Jing Lu, Yanchun Jia, Jia Liu, Jin Liu, Haiyan He, Xiaoxiang Wang, Xiaoqiang Fan, Lina Jin, Qianqi Ruan, Qi Zhang, Lianjun Shen, Lihong Weng, Wei Cao, Wenling Li, Juan Du
Journal: JAMA Oncology (2024)

Patients with high-risk newly diagnosed multiple myeloma (NDMM) often have poor outcomes with standard treatments, necessitating novel effective frontline therapies to enhance clinical outcomes. GC012F, a B-cell maturation antigen/CD19 dual-targeting chimeric antigen receptor (CAR) T-cell therapy, has been developed on the novel FasTCAR platform. Notably, its use as a frontline therapy for patients with high-risk NDMM who are eligible for transplant has not been thoroughly explored.
CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma
Authors: Ajaybabu V. Pobbati, Ashley Burtscher, Nandini Rajaram Siva, Andrea Hallett, Todd Romigh, Kepeng Che, Bin Zhao, Jesse A. Coker, Nancy Wang, Shaun R. Stauffer, Brian P. Rubin
Journal: Clinical Cancer Research (2024)

There are no effective treatment options for patients with aggressive epithelioid hemangioendothelioma (EHE) driven by the TAZ-CAMTA1 (TC) fusion gene. Here, we aimed to understand the regulation of TC using pharmacologic tools and identify vulnerabilities that can potentially be exploited for the treatment of EHE.
Population-Based Incidence of Cervical Intraepithelial Neoplasia Across 14 Years of HPV Vaccination
Authors: Rachael Adcock, Huining Kang, Philip E. Castle, Walter Kinney, Rebecca T. Emeny, Charles Wiggins, Cosette M. Wheeler
Journal: JAMA Oncology (2024)

This cohort study examines the incidence of cervical intraepithelial neoplasia during a period of increasing human papillomavirus (HPV) vaccination coverage from 2007 to 2020.
<i>BRCA1, BRCA2</i>, and Associated Cancer Risks and Management for Male Patients
Authors: Heather H. Cheng, Jeffrey W. Shevach, Elena Castro, Fergus J. Couch, Susan M. Domchek, Rosalind A. Eeles, Veda N. Giri, Michael J. Hall, Mary-Claire King, Daniel W. Lin, Stacy Loeb, Todd M. Morgan, Kenneth Offit, Colin C. Pritchard, Edward M. Schaeffer, Brittany M. Szymaniak, Jason L. Vassy, Bryson W. Katona, Kara N. Maxwell
Journal: JAMA Oncology (2024)

Half of all carriers of inherited cancer-predisposing variants in BRCA1 and BRCA2 are male, but the implications for their health are underrecognized compared to female individuals. Germline variants in BRCA1 and BRCA2 (also known as pathogenic or likely pathogenic variants, referred to here as BRCA1/2 PVs) are well known to significantly increase the risk of breast and ovarian cancers in female carriers, and knowledge of BRCA1/2 PVs informs established cancer screening and options for risk reduction. While risks to male carriers of BRCA1/2 PVs are less characterized, there is convincing evidence of increased risk for prostate cancer, pancreatic cancer, and breast cancer in males. There has also been a rapid expansion of US Food and Drug Administration-approved targeted cancer therapies, including poly ADP ribose polymerase (PARP) inhibitors, for breast, pancreatic, and prostate cancers associated with BRCA1/2 PVs.
Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure
Authors: Michael Birrer, Guiling Li, Mayu Yunokawa, Jung-Yun Lee, Byoung Gie Kim, Christina Pimentel Oppermann, Qi Zhou, Shin Nishio, Aikou Okamoto, Xiaohua Wu, Linda Mileshkin, Ana Oaknin, Isabelle Ray-Coquard, Kosei Hasegawa, Genevieve Jehl, Yulia Vugmeyster, Sen Zhang, Marcis Bajars, Kan Yonemori
Journal: JAMA Oncology (2024)

Cervical cancer is a common and lethal cancer worldwide. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor β receptor II (or transforming growth factor β trap) fused via a flexible linker to the C-terminus of each heavy chain of an immunoglobulin G1 antibody blocking programmed cell death 1 ligand 1.
Metabolic syndrome and cancer risk: A two-sample Mendelian randomization study of European ancestry
Authors: Lin Zhou, Huiyu Gao, Jiabin Zhang, Qian Xu, Qiang Wang, Li Wang, Ying Tan, Ziyuan Luo, Junjie Zhou, Hui Shuai, Xiang Cai, Yongbo Zheng, Shan Wang, Xi Duan, Tao Wus
Journal: International Journal of Surgery (2024)

The relationship between Metabolic Syndrome and cancer remains controversial. We aimed to assess the association between Metabolic Syndrome and cancer risk at different locations using a Mendelian randomization approach.
Immunotherapy Before Chemoradiotherapy—More Is Better?
Authors: Narjust Florez
Journal: JAMA Oncology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Cara
Authors: Danielle Chammas
Journal: JAMA Oncology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non–Small Cell Lung Cancer
Authors: Helen J. Ross, David Kozono, Xiaofei F. Wang, James John Urbanic, Terence M. Williams, Garth D. Nelson, David P. Carbone, Dongjun Chung, Ryan Robb, Woo Yul Byun, Tiffany Talabere, Carter DuFrane, Ilze Bara, Katja Schulze, Michelle Brockman, Junheng Gao, Everett E. Vokes, Thomas E. Stinchcombe
Journal: JAMA Oncology (2024)

Outcomes for patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiation therapy (CRT) have improved with adjuvant immune checkpoint inhibitors, with a reported 5-year overall survival benefit of approximately 10% for adjuvant durvalumab vs placebo after completion of CRT without progression and with preserved performance status. Starting atezolizumab prior to CRT may allow more patients to benefit from immunotherapy.
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
Authors: Fangfang Liu, Jingyu Chen, Kai Li, Haochen Li, Yiyi Zhu, Yubo Zhai, Bingbing Lu, Yanle Fan, Ziyue Liu, Xiaojie Chen, Xuechao Jia, Zigang Dong, Kangdong Liu
Journal: Molecular Cancer (2024)

Abstract Ubiquitination, a pivotal posttranslational modification of proteins, plays a fundamental role in regulating protein stability. The dysregulation of ubiquitinating and deubiquitinating enzymes is a common feature in various cancers, underscoring the imperative to investigate ubiquitin ligases and deubiquitinases (DUBs) for insights into oncogenic processes and the development of therapeutic interventions. In this review, we discuss the contributions of the ubiquitin–proteasome system (UPS) in all hallmarks of cancer and progress in drug discovery. We delve into the multiple functions of the UPS in oncology, including its regulation of multiple cancer-associated pathways, its role in metabolic reprogramming, its engagement with tumor immune responses, its function in phenotypic plasticity and polymorphic microbiomes, and other essential cellular functions. Furthermore, we provide a comprehensive overview of novel anticancer strategies that leverage the UPS, including the development and application of proteolysis targeting chimeras (PROTACs) and molecular glues.
Dimitriou M, Mortera-Blanco T, Tobiasson M, et al. Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation. <i>Blood.</i> 2024;143(11):953-966.
Journal: Blood (2024)

In supplemental Data files 1 through 4, an error occurred during conversion of the files to Microsoft Excel format.Consequently, some of the numbers in the columns headed "Cells (number)," "Ch1+ Ch2+," "Ch1+ Ch2-," "Ch1-Ch2+," and "Ch1-Ch2-" are rendered incorrectly with a decimal point; of those, some are also missing 1 or more significant zeros.The numbers affected by the error should have a comma to separate units of thousands.For example, in supplemental Data file 1, the second entry in the Ch1-Ch2+ column, 2.86, should be 2,860.The corrected supplemental Data files 1 through 4 are available in the HTML version of this erratum.
“Urological age” as a proxy of healthy longevity: analysis of prospective population-based cohorts in U.S. and China
Authors: Yuming Jin, Weichao Huang, Bin Zeng, Lu Yang, Shengfeng Wang, Colucci Manuel, Robesti Daniele, Linghui Deng, Siqi Leng, Dan Hu, Daming Wang, Zhongyuan Jiang, Qinling Yi, Li Zhang, Yuxiao Zeng, Wenjie Zhu, Li Sheng, Xinyue Liu, Qiang Wei, Shi Qiu
Journal: International Journal of Surgery (2024)

Assessing urinary symptoms poses a complex challenge for primary care practitioners. In evaluating urological function, our approach involves constructing an urological age through the analysis of laboratory parameters and indicators of the urinary system.
<i>Notes from the Field:</i> Health Monitoring, Testing, and Case Identification Among Persons Exposed to Influenza A(H5N1) — Michigan, 2024
Authors: Joseph Coyle, Natasha Bagdasarian, Seth Eckel, Jeremy Kuo, Mary Grace Stobierski, James Barber, Megan Weinberg, Fatema Mamou, Sarah Lyon-Callo, Jennifer Johnson, Dena Kent, Lisa Mikesell, Jennifer Morse, Becky Stoddard, Aimee Feehan, Chris May, Yolanda Rivera, Chad Shaw, Tamara Drake, Deral Glashower, Adeline Hambley, Gwen Unzicker, Rikki Fedewa, Susan Leeson, Clare Jansen, Kali Nichols, Maddie Vervaeke, Lisa Letts, Erin Radke, Elizabeth Baty, Darcie Cunningham, Kira Hecksel, Mary Huffman, Wai Yi Leung, Kassi Nelson, Sumeer Qurashi, Adenike Shoyinka, William Nettleton, Eric Pessell, Katie Margulieux, Diana Riner, Marty Soehnlen, Jalen Stricklen, Jason Wholehan, Smeralda Bushi, Derick Chia, Ebonē Colbert, Jim Collins, Justin Henderson, Tiffany Henderson, Shannon Johnson, Sue Kim, Mat Myers, Sarah Pruett, Briana Putrus, Bethany Reimink
Journal: MMWR Morbidity and Mortality Weekly Report (2024)
Endometriosis link with ovarian cancer … and other research
Authors: Ann Robinson
Journal: BMJ (2024)

Endometriosis and ovarian cancer riskEndometriosis affects around 11% of women of reproductive age and is an underlying cause of up to 50% of pelvic pain and female infertility.An additional worry is that having endometriosis carries a small increased risk of developing ovarian cancer.This large population-based cohort study from Utah found that women with incident endometriosis were 4.2 times more likely to develop ovarian cancer (7.48-fold increase in type I, 2.7-fold increase in type II) than those without endometriosis (in whom the estimated lifetime risk of ovarian cancer is around 2%).The worse the subtype of endometriosis, the higher the risk of ovarian cancer.Deep infiltrating endometriosis and/or ovarian endometriomas were associated with a 9.66-fold increased risk, whereas superficial peritoneal endometriosis and other endometriosis were associated with 2.82-fold and 2.62-fold increase respectively.Important questions remain.Why does endometriosis apparently increase the risk of ovarian cancer?What's the interaction with other known risk factors such as BRCA mutations?Are there novel treatment targets?And, most relevant for the women concerned, how should we advise, screen, and treat women plagued by this troublesome condition?
Effect of amino acid supplementation on short-term complications after gastrointestinal tumor surgery: the AMIGITS randomized clinical trial
Authors: Junke Wang, Yuezhi Chen, Zhiwen Zhao, Guodong Lian, Lipan Peng, Xinxiu Zhou, Shengxu Sha, Wenhao Qiao, Hui Tian, Leping Li, Feng Tian, Changqing Jing
Journal: International Journal of Surgery (2024)

Background: There is a scarcity of large randomized clinical trials on the efficacy and safety of high-dose amino acid supplementation (AAS) in patients with gastrointestinal tumors undergoing surgical treatment. Methods: This pragmatic, randomized, controlled, single-center, open-label, parallel-group AMIGITS trial was performed in a tertiary care teaching hospital. Patients with gastrointestinal tumors were randomly assigned to receive either AAS or standard care (SC). Amino acid targets were 2.0 g/kg per day in the AAS group and 1.2 g/kg per day in the SC group. The AAS group received additional amino acids intravenously, while the SC group received an iso-energetic 5% glucose intravenously. Results: Overall, 407 patients (AAS group, 204; SC group, 203) were included in this study. During the intervention, the actual mean daily energy intake did not differ significantly between the AAS and SC groups (25.53 vs. 25.16 kcal/kg per day, P =0.493). However, the actual mean daily amino acid intake was significantly higher in the AAS group than that in the SC group (1.81 vs. 0.94 g/kg per day, P &lt;0.001). The infection incidence during hospitalization and that within 30 days of surgery was significantly lower in the AAS group than that in the SC group ( P =0.031 and P= 0.024, respectively). The 30-day postoperative incidence of amino acid treatment-related adverse events and other complications did not significantly differ between the two groups. The postoperative hospital stay was significantly different between the two groups ( P&lt; 0.001). Conclusions: AAS was associated with a reduced infection incidence within 30 days of major surgery in patients with gastrointestinal tumors and can be a promising strategy.
Adult Smoking Cessation — United States, 2022
Authors: Brenna VanFrank, Ann Malarcher, Monica E. Cornelius, Anna Schecter, Ahmed Jamal, Michael Tynan
Journal: MMWR Morbidity and Mortality Weekly Report (2024)

Tobacco dependence is a chronic condition driven by nicotine addiction. Successful quitting can be increased by health care provider intervention and evidence-based treatment. CDC assessed national estimates of cigarette smoking cessation indicators among U.S. adults using 2022 National Health Interview Survey data. In 2022, approximately two thirds (67.7%) of the 28.8 million U.S. adults who smoked wanted to quit, and approximately one half (53.3%) made a quit attempt, but only 8.8% quit smoking. One half of adults who smoked and saw a health professional during the past year received health professional advice (50.5%) or assistance (49.2%) to quit smoking. Among those who tried to quit, 38.3% used treatment (i.e., counseling or medication). Adults who usually smoked menthol (versus nonmenthol) cigarettes had higher prevalences of quitting interest (72.2% versus 65.4%; p<0.05) and past-year quit attempts (57.3% versus 50.4%; p<0.05), lower prevalences of receiving quit advice (48.2% versus 53.8%; p<0.05) and using cessation treatment (35.2% versus 41.5%; p<0.05), but similar prevalence of quit success (9.5% versus 7.9%; p = 0.19). Opportunities exist for both public health and health care sectors to increase smoking cessation, including expanding access to and utilization of cessation services and supports. Incorporating equitable cessation strategies into all commercial tobacco prevention and control efforts can help advance and support smoking cessation for all population groups.
Suspected Counterfeit M-30 Oxycodone Pill Exposures and Acute Withdrawals Reported from a Single Hospital — Toxicology Investigators Consortium Core Registry, U.S. Census Bureau Western Region, 2017–2022
Authors: Emily Glidden, R. Matthew Gladden, Chris Dion, Meghan B. Spyres, Puja Seth, Kim Aldy, Desiree Mustaquim
Journal: MMWR Morbidity and Mortality Weekly Report (2024)

Availability of counterfeit prescription pills (counterfeit pills) containing illegally made fentanyl, including counterfeit M-30 oxycodone (counterfeit M-30) pills, has risen sharply in the United States and has been increasingly linked to overdose deaths.In 2023, approximately 115 million counterfeit pills were seized in U.S. High Intensity Drug Trafficking Areas.However, clinical data on counterfeit pill-related overdoses are limited.Medical toxicology consultations during 2017-2022 from one U.S. Census Bureau Western Region hospital participating in the Toxicology Investigators Consortium Core Registry were analyzed.A total of 352 cases suspected to involve counterfeit M-30 pills, including 143 (40.6%) cases of fentanyl exposure and 209 (59.4%) cases of acute withdrawal were identified; consultations increased from three in 2017, to 209 in 2022.Patients aged 15-34 years accounted for 95 (67.4%) exposure cases.Among all patients with exposures, 81.1% were hospitalized, 69.0% of whom were admitted to an intensive care unit.Additional substances were detected in 131 (91.6%) exposures.Providing outreach to younger persons misusing prescription pills, improving access to and distribution of harm reduction tools including fentanyl test strips and naloxone, and promoting linkage of persons treated for overdose in hospitals to harm reduction and substance use treatment services are strategies to reduce morbidity associated with use of counterfeit M-30.
Meta-analysis reveals higher intraoperative urologic complication rates in minimally invasive radical hysterectomy compared to abdominal radical hysterectomy
Authors: Jong Ha Hwang, Bitnarae Kim
Journal: International Journal of Surgery (2024)

Background: Minimally invasive radical hysterectomy (MIRH) has been increasingly adopted for its benefits of reduced blood loss and shorter hospital stays. This study aims to conduct a meta-analysis to compare the incidence of intraoperative urologic complications, including bladder and ureteral injuries, between MIRH and abdominal radical hysterectomy (ARH). Method: The authors systematically searched PubMed, EMBASE, and the Cochrane Library for studies published up to April 2024. A total of 35 studies were analyzed to compute odds ratios (ORs) for intraoperative urologic complications, bladder injuries, and ureteral injuries, focusing on subgroup evaluations by publication year, study quality, BMI, geographic region, and surgical method. Results: The meta-analysis demonstrates that MIRH is associated with higher risks of intraoperative urologic complications (OR=2.412, 95% CI: 1.995–2.916, P &lt;0.001), bladder injuries (OR=2.109, 95% CI: 1.567–2.839, P &lt;0.01), and ureteral injuries (OR=2.549, 95% CI: 1.992–3.262, P &lt;0.001). No publication bias was detected across the studies, ensuring the robustness of the findings. Significant differences in complication rates were also observed across geographic and procedural subgroups. Conclusion: The findings confirm that MIRH has a higher rate of intraoperative urologic complications, including bladder and ureteral injuries, compared to ARH. These results provide essential insights that could guide clinical decision-making and influence surgical practice guidelines.
Association between bariatric surgery and outcomes of total joint arthroplasty: a meta-analysis
Authors: Pan Liu, Jiahao Meng, Hang Tang, Yifan Xiao, Xi Li, Yumei Wu, Weijie Liu, Yilin Xiong, Shuguang Gao
Journal: International Journal of Surgery (2024)

Liu, Pan BS; Meng, Jiahao BS; Tang, Hang BS; Xiao, Yifan BS; Li, Xi BS; Wu, Yumei BS; Liu, Weijie; Xiong, Yilin MD; Gao, Shuguang MD Author Information